RU2017140269A - NEW POLYMORPHIC FORMS OF TRIMEBUTIN MALEAT, METHOD OF OBTAINING AND APPLICATION - Google Patents

NEW POLYMORPHIC FORMS OF TRIMEBUTIN MALEAT, METHOD OF OBTAINING AND APPLICATION Download PDF

Info

Publication number
RU2017140269A
RU2017140269A RU2017140269A RU2017140269A RU2017140269A RU 2017140269 A RU2017140269 A RU 2017140269A RU 2017140269 A RU2017140269 A RU 2017140269A RU 2017140269 A RU2017140269 A RU 2017140269A RU 2017140269 A RU2017140269 A RU 2017140269A
Authority
RU
Russia
Prior art keywords
polymorphic form
trimebutin
maleat
obtaining
application
Prior art date
Application number
RU2017140269A
Other languages
Russian (ru)
Other versions
RU2706166C2 (en
RU2017140269A3 (en
Inventor
Кирилл Константинович Сыров
Владимир Викторович Нестерук
Original Assignee
Общество С Ограниченной Ответственностью "Валента - Интеллект"
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=66540370&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2017140269(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Общество С Ограниченной Ответственностью "Валента - Интеллект" filed Critical Общество С Ограниченной Ответственностью "Валента - Интеллект"
Priority to RU2017140269A priority Critical patent/RU2706166C2/en
Priority to KR1020207016962A priority patent/KR102509190B1/en
Priority to CN201880074646.0A priority patent/CN111432811B/en
Priority to PCT/RU2018/000729 priority patent/WO2019098883A1/en
Priority to UAA202003442A priority patent/UA124755C2/en
Priority to EA202091237A priority patent/EA202091237A1/en
Priority to BR112020010135-4A priority patent/BR112020010135A2/en
Publication of RU2017140269A publication Critical patent/RU2017140269A/en
Publication of RU2017140269A3 publication Critical patent/RU2017140269A3/ru
Publication of RU2706166C2 publication Critical patent/RU2706166C2/en
Application granted granted Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C219/00—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C219/02—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C219/18—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C219/00—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C219/02—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C219/20—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated
    • C07C219/22—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Claims (3)

1. Полиморфная форма тримебутина малеата, отличающаяся тем, что упомянутая полиморфная форма имеет на порошковой рентгеновской дифрактограмме характеристические пики при следующих углах 2θ, ° (± 0,1°): 8,7; 11,6; 13,2; 15,3; 17,6; 20,1; 20,3; 20,8; 21,5; 23,4; 24,7; 25,4; 27,3; 27,9; 30,8; 34,7; 35,8; 39,1; 45,0.1. The polymorphic form of trimebutine maleate, characterized in that the said polymorphic form has on the powder X-ray diffractogram characteristic peaks at the following angles 2θ, ° (± 0.1 °): 8.7; 11.6; 13.2; 15.3; 17.6; 20.1; 20.3; 20.8; 21.5; 23.4; 24.7; 25.4; 27.3; 27.9; 30.8; 34.7; 35.8; 39.1; 45.0. 2. Фармацевтическая композиция для лечения синдрома раздраженного кишечника, послеоперационной паралитической кишечной непроходимости, подготовки к рентгенологическому и эндоскопическому исследованиям ЖКТ, отличающаяся тем, что упомянутая композиция содержит в терапевтически эффективном количестве полиморфную форму тримебутина малеата по п. 1 и по меньшей мере один фармацевтически приемлемый носитель.2. Pharmaceutical composition for treating irritable bowel syndrome, postoperative paralytic intestinal obstruction, preparation for X-ray and endoscopic studies of the gastrointestinal tract, characterized in that the said composition contains in a therapeutically effective amount of the polymorphic form of the trimebutine maleate according to claim 1 and at least one pharmaceutically acceptable carrier . 3. Лекарственное средство для лечения синдрома раздраженного кишечника, послеоперационной паралитической кишечной непроходимости, для подготовки к рентгенологическому и эндоскопическому исследованиям ЖКТ в форме таблеток, капсул или инъекций, помещенных в фармацевтически приемлемую упаковку, отличающееся тем, что упомянутое средство содержит в терапевтически эффективном количестве полиморфную форму по п. 1 или фармацевтическую композицию по п. 2.3. Drug for the treatment of irritable bowel syndrome, postoperative paralytic intestinal obstruction, to prepare for X-ray and endoscopic studies of the gastrointestinal tract in the form of tablets, capsules or injections, placed in a pharmaceutically acceptable package, characterized in that the said agent contains a polymorphic form in a therapeutically effective amount According to claim 1 or the pharmaceutical composition according to claim 2.
RU2017140269A 2017-11-20 2017-11-20 Novel polymorphic forms of trimebutine maleate, method for production and use thereof RU2706166C2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
RU2017140269A RU2706166C2 (en) 2017-11-20 2017-11-20 Novel polymorphic forms of trimebutine maleate, method for production and use thereof
UAA202003442A UA124755C2 (en) 2017-11-20 2018-11-08 Polymorphic forms of trimebutine maleate and method of using same
CN201880074646.0A CN111432811B (en) 2017-11-20 2018-11-08 Polymorphs of trimebutine maleate and methods of use thereof
PCT/RU2018/000729 WO2019098883A1 (en) 2017-11-20 2018-11-08 Polymorphic forms of trimebutine maleate and method of using same
KR1020207016962A KR102509190B1 (en) 2017-11-20 2018-11-08 Polymorphs of trimebutine maleate and methods of use thereof
EA202091237A EA202091237A1 (en) 2017-11-20 2018-11-08 NEW POLYMORPHIC FORMS OF TRIMEBUTIN MALEATE, METHOD OF OBTAINING AND APPLICATION
BR112020010135-4A BR112020010135A2 (en) 2017-11-20 2018-11-08 polymorphic forms of trimebutine maleate and method of using them

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU2017140269A RU2706166C2 (en) 2017-11-20 2017-11-20 Novel polymorphic forms of trimebutine maleate, method for production and use thereof

Related Child Applications (2)

Application Number Title Priority Date Filing Date
RU2019132977A Division RU2770300C2 (en) 2019-10-17 2019-10-17 New polymorphic forms of trimebutine maleate, method for production and application
RU2019132971A Division RU2770301C2 (en) 2019-10-17 2019-10-17 New polymorphic forms of trimebutine maleate, method for production and application

Publications (3)

Publication Number Publication Date
RU2017140269A true RU2017140269A (en) 2019-05-20
RU2017140269A3 RU2017140269A3 (en) 2019-05-20
RU2706166C2 RU2706166C2 (en) 2019-11-14

Family

ID=66540370

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2017140269A RU2706166C2 (en) 2017-11-20 2017-11-20 Novel polymorphic forms of trimebutine maleate, method for production and use thereof

Country Status (7)

Country Link
KR (1) KR102509190B1 (en)
CN (1) CN111432811B (en)
BR (1) BR112020010135A2 (en)
EA (1) EA202091237A1 (en)
RU (1) RU2706166C2 (en)
UA (1) UA124755C2 (en)
WO (1) WO2019098883A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2752086C1 (en) * 2020-04-27 2021-07-22 Общество С Ограниченной Ответственностью "Валента-Интеллект" New [2-(dimethylamino)-2-phenylbutyl]-3,4,5-trimetoxybenzoate 4-methyl-2h-chromen-2-on-7-ilsulphate compound and application thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2131804B1 (en) * 1971-03-12 1974-03-22 Jouveinal Sa
FR2752162B1 (en) * 1996-08-07 1998-11-06 Jouveinal Lab TRIMEBUTINE FILM MALEATE TABLET
CN102188389B (en) * 2010-03-18 2014-04-02 杭州赛利药物研究所有限公司 Trimebutine Maleate suspension and preparation method thereof
KR101220829B1 (en) * 2010-07-16 2013-01-10 안국약품 주식회사 Sustained-release tablet containing trimebutine
EP2481403A1 (en) * 2011-02-01 2012-08-01 Deva Holding Anonim Sirketi Pharmaceutical combination of otilonium and trimebutine
CN104254517A (en) * 2012-03-12 2014-12-31 吉卡尔制药公司 Novel sulfonate-based trimebutine salts

Also Published As

Publication number Publication date
BR112020010135A2 (en) 2021-03-23
UA124755C2 (en) 2021-11-10
RU2706166C2 (en) 2019-11-14
WO2019098883A1 (en) 2019-05-23
EA202091237A1 (en) 2020-08-17
KR20200110308A (en) 2020-09-23
KR102509190B1 (en) 2023-03-14
CN111432811A (en) 2020-07-17
RU2017140269A3 (en) 2019-05-20
CN111432811B (en) 2023-06-23

Similar Documents

Publication Publication Date Title
JP2016041701A5 (en)
JP2013237682A5 (en)
JP2021503480A5 (en)
JP2008533127A5 (en)
JP2015522589A5 (en)
RU2017111590A (en) CRYSTALLINE FORMS 2- (4- (4-ETOXY-6-OXO-1,6-DIHYDROPYRIDIN-3-IL) -2-fluorophenyl) -N- (5- (1,1,1-TRIFTOR-2-METILPROPAN- 2-yl) isoxazole-3-yl) acetamide
IN2013MN01519A (en)
JP2015537009A5 (en)
JP2009505991A5 (en)
WO2011045232A3 (en) Neuropeptide-2 receptor (y-2r) agonists
JP2007532560A5 (en)
RU2017107760A (en) Compound
RU2015142255A (en) PHARMACEUTICAL COMBINED MEDICINE
JP2015516425A5 (en)
JP2015514797A5 (en)
JP2016539136A5 (en)
RU2017139002A (en) PIROGLUTAMAT VORTIOKSETINA
RU2017140269A (en) NEW POLYMORPHIC FORMS OF TRIMEBUTIN MALEAT, METHOD OF OBTAINING AND APPLICATION
JP2014527506A5 (en)
WO2012067481A3 (en) Orally administered pharmaceutical composition for the treatment of irritable bowel syndrome, comprising an intestinal motility modifier, an agent that prevents gas retention, and digestive enzymes, and preparation method thereof
WO2011080502A3 (en) New pharmaceutical dosage form for the treatment of gastric acid-related disorders
JP2019085364A5 (en)
ZA201304157B (en) Orally administered pharmaceutical composition and preparation method thereof,for the prevention and treatment of irritable bowel syndrome,comprising an intestinal motility modifier and a-d-galactosidase
RU2019132971A (en) NEW POLYMORPHIC FORMS OF TRIMEBUTIN MALEATE, METHOD OF OBTAINING AND APPLICATION
RU2019132977A (en) NEW POLYMORPHIC FORMS OF TRIMEBUTIN MALEATE, METHOD OF OBTAINING AND APPLICATION

Legal Events

Date Code Title Description
QB4A Licence on use of patent

Free format text: LICENCE FORMERLY AGREED ON 20200416

Effective date: 20200416

PD4A Correction of name of patent owner